My Courses

Fincast founder Benjamin Schieken joins RegFi co-hosts Jerry Buckley and Sherry Safchuk to discuss how AI-enabled technology can transform the mortgage shopping process by enabling consumers to compare loan options more effectively and introducing greater competition among lenders. This evolving digital approach considers not only APR, but also total transaction costs and the likely duration…

In April 2026, the U.S. Department of Health and Human Services Office for Civil Rights (OCR) released “Risk Management Under the HIPAA Security Rule,” a YouTube presentation addressing the Health Insurance Portability and Accountability Act (HIPAA) Security Rule’s risk management requirement….By: BakerHostetler

State AGs are doubling down—across party lines—on consumer protection, with a sharp focus on vulnerable groups and increased scrutiny of algorithmic pricing models and online age‑verification practices….By: Benesch

You just closed a funding round. The wire hit, the board is excited, and it may feel like someone pressed the big red “launch” button. Securing capital is not crossing a finish line; it is strapping your company to a rocket. The engines ignite, the acceleration is real, and the goal is clear: achieve orbit,…

When it comes to evaluating bills submitted to PIP carriers in Delaware, insureds often ask whether, pursuant to Delaware law, carriers are required to pay only those amounts billed/charged by medical practitioners that are “ordinary and customary.” Delaware law is unique when it comes to consideration of this issue….By: Marshall Dennehey

The Product Liability & Mass Tort Monitor is a monthly newsletter delivering critical updates, data insights and actionable strategies for navigating the complexities of product liability and mass tort litigation. This month’s issue looks at the Supreme Court’s review of FIFRA preemption and the potential implications for product liability litigation….By: McGuireWoods LLP

If you or a loved one was diagnosed with cutaneous T-cell lymphoma (CTCL) while taking Dupixent, you may be wondering whether it is still possible to file a lawsuit. For many patients and families, the answer is yes — but legal deadlines are firm, and the window to act will not stay open indefinitely….By: Morris…

National or multi-jurisdictional class actions are common in Canada, regularly giving rise to parallel and overlapping cases across multiple provinces. This often happens in life sciences litigation, where claims relating to the same drug or device are advanced in multiple jurisdictions, leading to carriage disputes and allegations of abuse of process. Without a national framework…